TLDR
- Clorox stock hit a new 52-week low of $91.00, later falling to $88.38, down 27.25% over the past year
- Q3 FY2026 EPS came in at $1.64, beating estimates by $0.10, but revenue guidance was cut
- Clorox now projects a net sales decline of ~6% for fiscal year 2026
- Goldman Sachs, UBS, Morgan Stanley, and Evercore ISI all cut their price targets on CLX
- Multiple analysts maintain cautious outlooks despite the earnings beat
Clorox (CLX) stock hit a new 52-week low of $91.00 on May 1, before sliding further to $88.38. The stock is now down 27.25% over the past year.
The drop came after Clorox reported Q3 FY2026 earnings on April 30 and trimmed its full-year outlook.
On the surface, the quarter wasn’t bad. Non-GAAP EPS came in at $1.64, beating analyst estimates of $1.55 by $0.10. Revenue landed at $1.67 billion, in line with forecasts.
📊 Clorox $CLX Q3 Earnings ✅ Earnings Beat
Adj. EPS: $1.64
YoY: ↑ 13% (from $1.45)✅ Revenue Beat
Sales: $1.670B
YoY: Flat (from $1.668B)CLX with the classic household staple move — tiny beats on both lines while revenue is basically dead flat. Bleach and trash bags…
— CHItrader (@CHItrader) April 30, 2026
But guidance told a different story. Clorox now expects a net sales decline of roughly 6% for fiscal year 2026. That’s a notable step back from its previous forecast.
Adjusted EPS guidance for the full year was also cut, now expected between $5.45 and $5.65, down from the prior range of $5.95 to $6.30.
The stock dipped around 2% immediately following the earnings release.
Wall Street Cuts Price Targets
The revised outlook triggered a wave of price target reductions from major firms.
Goldman Sachs cut its target to $83 from $94, directly citing the guidance reduction as the key driver.
UBS trimmed its target to $96 from $110 while keeping a Neutral rating. Morgan Stanley also dropped its target, moving to $97 from $110, pointing to sales challenges in certain product categories.
Evercore ISI reduced its target to $110 from $115, flagging that Q3 results included a benefit from the elimination of Glad’s royalty payments — a one-time tailwind that won’t repeat.
Mixed Picture on Fundamentals
Clorox’s current P/E ratio sits at 15.76x, which some analysts view as a modest valuation relative to earnings. InvestingPro data suggests the stock looks undervalued at current levels.
GF Score rates CLX at 68 out of 100. Profitability scores well at 7/10, but growth ranks just 1/10 — a concern in a competitive consumer goods market.
Financial strength is rated 4/10, pointing to potential pressure on debt management and cash flow.
Clorox noted that the GOJO acquisition is expected to partially offset the revenue decline, though the overall tone remains cautious.
Insider activity over the past 12 months has been limited — two buys and one sell, with the sell totaling roughly $1.86 million.
The company’s market cap now sits at approximately $11.66 billion, a steep decline from where it traded a year ago.
The 52-week low of $88.38 is the most recent marker for a stock that has been grinding lower throughout the fiscal year.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
